Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Numata M, Chu HW, Dakhama A, Voelker DR.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):320-5. doi: 10.1073/pnas.0909361107. Epub 2009 Dec 22.

2.

Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.

Numata M, Nagashima Y, Moore ML, Berry KZ, Chan M, Kandasamy P, Peebles RS Jr, Murphy RC, Voelker DR.

J Lipid Res. 2013 Aug;54(8):2133-43. doi: 10.1194/jlr.M037077. Epub 2013 Jun 6.

3.

Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.

Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA, Gioannini TL, Weiss JP, Chow JC, Hawkins LD, Vogel SN, Blanco JC.

MBio. 2012 Aug 7;3(4). pii: e00218-12. doi: 10.1128/mBio.00218-12. Print 2012.

4.

Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung.

Numata M, Grinkova YV, Mitchell JR, Chu HW, Sligar SG, Voelker DR.

Int J Nanomedicine. 2013;8:1417-27. doi: 10.2147/IJN.S39888. Epub 2013 Apr 15.

5.

Phosphatidylglycerol suppresses influenza A virus infection.

Numata M, Kandasamy P, Nagashima Y, Posey J, Hartshorn K, Woodland D, Voelker DR.

Am J Respir Cell Mol Biol. 2012 Apr;46(4):479-87. doi: 10.1165/rcmb.2011-0194OC. Epub 2011 Nov 3.

6.

Alleviation of respiratory syncytial virus replication and inflammation by fungal immunomodulatory protein FIP-fve from Flammulina velutipes.

Chang YC, Chow YH, Sun HL, Liu YF, Lee YT, Lue KH, Ko JL.

Antiviral Res. 2014 Oct;110:124-31. doi: 10.1016/j.antiviral.2014.08.006. Epub 2014 Aug 14.

PMID:
25131377
7.

Antiviral activity of ginseng extract against respiratory syncytial virus infection.

Lee JS, Ko EJ, Hwang HS, Lee YN, Kwon YM, Kim MC, Kang SM.

Int J Mol Med. 2014 Jul;34(1):183-90. doi: 10.3892/ijmm.2014.1750. Epub 2014 Apr 22.

8.

Surfactant protein-A enhances respiratory syncytial virus clearance in vivo.

LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T.

J Clin Invest. 1999 Apr;103(7):1015-21.

9.

Effects of primary and secondary low-grade respiratory syncytial virus infections in a murine model of asthma.

Kondo Y, Matsuse H, Machida I, Kawano T, Saeki S, Tomari S, Obase Y, Fukushima C, Kohno S.

Clin Exp Allergy. 2004 Aug;34(8):1307-13.

PMID:
15298574
10.

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.

Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A.

Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13.

PMID:
23499594
11.

Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Zeng R, Zhang H, Hai Y, Cui Y, Wei L, Li N, Liu J, Li C, Liu Y.

J Virol. 2012 Apr;86(8):4505-17. doi: 10.1128/JVI.07091-11. Epub 2012 Feb 1.

12.

Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.

Ohol YM, Wang Z, Kemble G, Duke G.

PLoS One. 2015 Dec 11;10(12):e0144648. doi: 10.1371/journal.pone.0144648. eCollection 2015 Dec 11.

13.

Increased pathogenesis and inflammation of airways from respiratory syncytial virus infection in T cell deficient nude mice.

Zhou J, Yang XQ, Fu Z, Zhao XD, Jiang LP, Wang LJ, Cui YX.

Med Microbiol Immunol. 2008 Dec;197(4):345-51. Epub 2007 Dec 5.

PMID:
18058127
14.
15.

Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans.

Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Böttcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J, Davidson DJ.

J Immunol. 2016 Mar 15;196(6):2699-710. doi: 10.4049/jimmunol.1502478. Epub 2016 Feb 12.

17.

Ultrafine carbon black particles enhance respiratory syncytial virus-induced airway reactivity, pulmonary inflammation, and chemokine expression.

Lambert AL, Mangum JB, DeLorme MP, Everitt JI.

Toxicol Sci. 2003 Apr;72(2):339-46. Epub 2003 Mar 7.

PMID:
12655033
18.
19.

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.

Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M.

Virology. 2000 Mar 30;269(1):54-65.

20.

Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice.

Zang N, Xie X, Deng Y, Wu S, Wang L, Peng C, Li S, Ni K, Luo Y, Liu E.

J Virol. 2011 Dec;85(24):13061-8. doi: 10.1128/JVI.05869-11. Epub 2011 Sep 21.

Supplemental Content

Support Center